The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.
β-Catenin signaling in hepatocellular carcinoma
Open accessAbstract
Deregulated Wnt/β-catenin signaling is one of the main genetic alterations in human hepatocellular carcinoma (HCC). Comprehensive genomic analyses have revealed that gain-of-function mutation of CTNNB1, which encodes β-catenin, and loss-of-function mutation of AXIN1 occur in approximately 35% of human HCC samples. Human HCCs with activation of the Wnt/β-catenin pathway demonstrate unique gene expression patterns and pathological features. Activated Wnt/β-catenin synergizes with multiple signaling cascades to drive HCC formation, and it functions through its downstream effectors. Therefore, strategies targeting Wnt/β-catenin have been pursued as possible therapeutics against HCC. Here, we review the genetic alterations and oncogenic roles of aberrant Wnt/β-catenin signaling during hepatocarcinogenesis. In addition, we discuss the implication of this pathway in HCC diagnosis, classification, and personalized treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Identification of c- MYC as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Wnt signalling in stem cells and cancer
Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666 · cited 1×
“Molecular mechanisms of Wnt/β-catenin activation in HCC The Wnt/β-catenin cascade is one of the major signaling pathways regulating liver homeostasis, regeneration, and tumorigenesis (10), which has been extensively reviewed (11, 12).”
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“Likewise, activated β-catenin in melanoma cells enhances ATF3 expression and subsequently represses CCL4 expression, leading to reduced recruitment of dendritic cells and consequently T cells into the tumor tissues (142).”
mTOR at the nexus of nutrition, growth, ageing and disease
Liu, G. Y., & Sabatini, D. M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0199-y · Cited by 2,737
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., & Ben-Ze’ev, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5522 · Cited by 2,230
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Huang, S.-M. A., Mishina, Y. M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G. A., Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., et al. (2009) · Nature · doi:10.1038/nature08356 · Cited by 2,037
Self-citationGlobal epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Caught up in a Wnt storm: Wnt signaling in cancer
Giles, R. H., van Es, J. H., & Clevers, H. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00005-2 · Cited by 1,482
Molecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,439
NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5785 · Cited by 1,312
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238 · cited 1×
“Overall, human HCCs can be subdivided into two major groups: a proliferation group and a nonproliferation group (36, 37).”
Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas
Coste, A. D. L., Romagnolo, B., Billuart, P., Renard, C.-A., Buendia, M.-A., Soubrane, O., Fabre, M., Chelly, J., Beldjord, C., Kahn, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8847 · Cited by 1,121
Lustig, B., Jerchow, B., Sachs, M., Weiler, S., Pietsch, T., Karsten, U., van de Wetering, M., Clevers, H., Schlag, P. M., Birchmeier, W., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.4.1184-1193.2002 · Cited by 1,036
Sangro, B., Gomez-Martin, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., Riezu-Boj, J. I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.022 · Cited by 980
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
Lee, J.-S., Heo, J., Libbrecht, L., Chu, I.-S., Kaposi-Novak, P., Calvisi, D. F., Mikaelyan, A., Roberts, L. R., Demetris, A. J., Sun, Z., et al. (2006) · Nature Medicine · doi:10.1038/nm1377 · Cited by 953
Self-citationRuiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912 · cited 1×
“Furthermore, studies using mouse HCC models confirmed that upregulated Wnt/β-catenin signaling in HCC promotes immune evasion and confers resistance to anti–PD-1 therapy (141).”
A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J.-L., Oh, S. W., Kim, H. Y., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404875101 · Cited by 874
Monounsaturated Fatty Acid Modification of Wnt Protein: Its Role in Wnt Secretion
Takada, R., Satomi, Y., Kurata, T., Ueno, N., Norioka, S., Kondoh, H., Takao, T., & Takada, S. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.003 · Cited by 788
Calderaro, J., Couchy, G., Imbeaud, S., Amaddeo, G., Letouzé, E., Blanc, J.-F., Laurent, C., Hajji, Y., Azoulay, D., Bioulac-Sage, P., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.014 · Cited by 780
Wnt/beta-catenin pathway: modulating anticancer immune response
Pai, S. G., Carneiro, B. A., Mota, J. M., Costa, R., Leite, C. A., Barroso-Sousa, R., Kaplan, J. B., Chae, Y. K., & Giles, F. J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0471-6 · Cited by 703
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex
Lepourcelet, M., Chen, Y.-N. P., France, D. S., Wang, H., Crews, P., Petersen, F., Bruseo, C., Wood, A. W., & Shivdasani, R. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00334-9 · Cited by 653
Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614 · cited 1×
“Therapeutic monoclonal antibodies against Wnts were also developed to block the binding of Wnts to Frizzled (FZ/FZD) receptors, such as anti-Wnt2 monoclonal antibodies (110) and the anti-FZD monoclonal antibody OMP-18R5 (111).”
Wnt–β-catenin signalling in liver development, health and disease
Perugorria, M. J., Olaizola, P., Labiano, I., Esparza-Baquer, A., Marzioni, M., Marin, J. J. G., Bujanda, L., & Banales, J. M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0075-9 · Cited by 605
Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., Shia, J., Hechtman, J. F., Kundra, R., El Dika, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2293 · Cited by 602 · cited 1×
“reported that in HCC patients treated with ICIs, activation of the Wnt/β-catenin pathway correlates with lower disease control rate and lower progression-free and overall survival rates (140).”
Advances in molecular classification and precision oncology in hepatocellular carcinoma
Rebouissou, S., & Nault, J.-C. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.017 · Cited by 575
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beg, M. S., Brower, S. T., Gade, T. P., Goff, L., Gupta, S., Guy, J., Harris, W. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02672 · Cited by 570
Zhu, A. X., Kudo, M., Assenat, E., Cattan, S., Kang, Y.-K., Lim, H. Y., Poon, R. T. P., Blanc, J.-F., Vogel, A., Chen, C.-L., et al. (2014) · JAMA · doi:10.1001/jama.2014.7189 · Cited by 568
Crosstalk between Wnt/β-Catenin and NF-κB Signaling Pathway during Inflammation
Ma, B., & Hottiger, M. O. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00378 · Cited by 563
Apc Tumor Suppressor Gene Is the “Zonation-Keeper” of Mouse Liver
Benhamouche, S., Decaens, T., Godard, C., Chambrey, R., Rickman, D. S., Moinard, C., Vasseur-Cognet, M., Kuo, C. J., Kahn, A., Perret, C., et al. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.03.015 · Cited by 543 · cited 1×
“In the normal liver, β-catenin is membrane-localized in hepatocytes, and the Wnt/β-catenin pathway is activated in pericentral hepatocytes, which is demonstrated by β-catenin–dependent glutamine synthetase (GS) staining in these cells (13, 14).”
Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor
Krall, A. S., Xu, S., Graeber, T. G., Braas, D., & Christofk, H. R. (2016) · Nature Communications · doi:10.1038/ncomms11457 · Cited by 504
β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis
Monga, S. P. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.056 · Cited by 487
Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α
Thorne, C. A., Hanson, A. J., Schneider, J., Tahinci, E., Orton, D., Cselenyi, C. S., Jernigan, K. K., Meyers, K. C., Hang, B. I., Waterson, A. G., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.453 · Cited by 485
Mutations and mechanisms of WNT pathway tumour suppressors in cancer
Bugter, J. M., Fenderico, N., & Maurice, M. M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00307-z · Cited by 466 · cited 1×
“APC and AXIN1 mutations are mostly missense, deleted, and/or truncated mutations, resulting in loss of protein expression and function, a characteristic of tumor suppressors (17).”
Activation of Hepatic Stem Cell Marker EpCAM by Wnt–β-Catenin Signaling in Hepatocellular Carcinoma
Yamashita, T., Budhu, A., Forgues, M., & Wang, X. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0908 · Cited by 446
Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research
Chen, X., & Calvisi, D. F. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.12.002 · Cited by 434
Self-citationNew targets of β-catenin signaling in the liver are involved in the glutamine metabolism
Cadoret, A., Ovejero, C., Terris, B., Souil, E., Lévy, L., Lamers, W. H., Kitajewski, J., Kahn, A., & Perret, C. (2002) · Oncogene · doi:10.1038/sj.onc.1206118 · Cited by 410
Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets
Klingenberg, M., Matsuda, A., Diederichs, S., & Patel, T. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.009 · Cited by 354
Wong, C. M., Fan, S. T., & Ng, I. O. L. (2001) · Cancer · doi:10.1002/1097-0142(20010701)92:1<136::aid-cncr1301>3.0.co;2-r · Cited by 348
Transcriptional regulation of the cyclin D1 gene at a glance
Klein, E. A., & Assoian, R. K. (2008) · Journal of Cell Science · doi:10.1242/jcs.039131 · Cited by 341
Projections of primary liver cancer to 2030 in 30 countries worldwide
Valery, P. C., Laversanne, M., Clark, P. J., Petrick, J. L., McGlynn, K. A., & Bray, F. (2018) · Hepatology · doi:10.1002/hep.29498 · Cited by 330
Waaler, J., Machon, O., Tumova, L., Dinh, H., Korinek, V., Wilson, S. R., Paulsen, J. E., Pedersen, N. M., Eide, T. J., Machonova, O., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3336 · Cited by 328
Regulation of c-myc expression by IFN-γ through Stat1-dependent and -independent pathways
Ramana, C. V., Grammatikakis, N., Chernov, M., Nguyen, H., Chuan Goh, K., Williams, B. R. G., & Stark, G. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.2.263 · Cited by 319
Tao, J., Calvisi, D. F., Ranganathan, S., Cigliano, A., Zhou, L., Singh, S., Jiang, L., Fan, B., Terracciano, L., Armeanu–Ebinger, S., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.05.004 · Cited by 317
Self-citationA Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4562 · Cited by 316
Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
Matter, M. S., Decaens, T., Andersen, J. B., & Thorgeirsson, S. S. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.031 · Cited by 314
Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment
Vilchez, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.823 · Cited by 312
Nhieu, J. T. V., Renard, C. A., Wei, Y., Cherqui, D., Zafrani, E. S., & Buendia, M. A. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65168-1 · Cited by 295
Sekine, S., Lan, B. Y., Bedolli, M., Feng, S., & Hebrok, M. (2006) · Hepatology · doi:10.1002/hep.21131 · Cited by 295
Peng, S., Chen, W. J., Lai, P., Jeng, Y., Sheu, J., & Hsu, H. (2004) · International Journal of Cancer · doi:10.1002/ijc.20279 · Cited by 295
Pez, F., Lopez, A., Kim, M., Wands, J. R., Caron de Fromentel, C., & Merle, P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.001 · Cited by 294
Hsu, H.-C., Jeng, Y.-M., Mao, T.-L., Chu, J.-S., Lai, P.-L., & Peng, S.-Y. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64590-7 · Cited by 294
Huang, H., Fujii, H., Sankila, A., Mahler-Araujo, B. M., Matsuda, M., Cathomas, G., & Ohgaki, H. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65496-x · Cited by 274
You, L., He, B., Xu, Z., Uematsu, K., Mazieres, J., Mikami, I., Reguart, N., Moody, T. W., Kitajewski, J., McCormick, F., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207844 · Cited by 258
Self-citationBeta-catenin signaling in murine liver zonation and regeneration: A Wnt-Wnt situation!
Yang, J., Mowry, L. E., Nejak-Bowen, K. N., Okabe, H., Diegel, C. R., Lang, R. A., Williams, B. O., & Monga, S. P. (2014) · Hepatology · doi:10.1002/hep.27082 · Cited by 244
Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance
Khalaf, A. M., Fuentes, D., Morshid, A. I., Burke, M. R., Kaseb, A. O., Hassan, M., Hazle, J. D., & Elsayes, K. M. (2018) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s156701 · Cited by 227
Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma
Sukhdeo, K., Mani, M., Zhang, Y., Dutta, J., Yasui, H., Rooney, M. D., Carrasco, D. E., Zheng, M., He, H., Tai, Y.-T., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610299104 · Cited by 216
Self-citationCommon dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma
Bengochea, A., de Souza, M. M., Lefrançois, L., Le Roux, E., Galy, O., Chemin, I., Kim, M., Wands, J. R., Trepo, C., Hainaut, P., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604422 · Cited by 215 · cited 1×
“These include promoter hypermethylation and related silencing of the secreted Frizzledrelated protein 1 gene (SFRP1), a Wnt/β-catenin antagonist (18); overexpression of Frizzled (FZD) membrane receptor and Wnt ligands (19); and deregulated expression of microRNAs (20) and long noncoding RNAs (21) that regulate Wnt/β-c…”
Wnt/?-catenin-pathway as a molecular target for future anti-cancer therapeutics
Dihlmann, S., & von Knebel Doeberitz, M. (2005) · International Journal of Cancer · doi:10.1002/ijc.20609 · Cited by 201
Hepatocarcinogenesis in Mice with β-Catenin and Ha-Ras Gene Mutations
Harada, N., Oshima, H., Katoh, M., Tamai, Y., Oshima, M., & Taketo, M. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2123 · Cited by 194
Boon, E. M. J., Keller, J. J., Wormhoudt, T. A. M., Giardiello, F. M., Offerhaus, G. J. A., van der Neut, R., & Pals, S. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601505 · Cited by 190
Liu, L., Zhu, X.-D., Wang, W.-Q., Shen, Y., Qin, Y., Ren, Z.-G., Sun, H.-C., & Tang, Z.-Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2610 · Cited by 183
Dubik, D., & Shiu, R. P. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)37810-4 · Cited by 182
Torrecilla, S., Sia, D., Harrington, A. N., Zhang, Z., Cabellos, L., Cornella, H., Moeini, A., Camprecios, G., Leow, W.-Q., Fiel, M. I., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.08.013 · Cited by 181
Arqués, O., Chicote, I., Puig, I., Tenbaum, S. P., Argilés, G., Dienstmann, R., Fernández, N., Caratù, G., Matito, J., Silberschmidt, D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3081 · Cited by 178
Unique phenotype of hepatocellular cancers with exon‐3 mutations in beta‐catenin gene†
Cieply, B., Zeng, G., Proverbs‐Singh, T., Geller, D. A., & Monga, S. P. S. (2009) · Hepatology · doi:10.1002/hep.22695 · Cited by 174
Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin.
Cadoret, A., Ovejero, C., Saadi-Kheddouci, S., Souil, E., Fabrè, M., Romagnolo, B., Kahn, A., & Perret, C. (2001) · PubMed · Cited by 169
Cholestasis is a marker for hepatocellular carcinomas displaying β‐catenin mutations
Audard, V, Grimber, G., Elie, C., Radenen, B., Audebourg, A., Letourneur, F., Soubrane, O., Vacher‐Lavenu, M., Perret, C., Cavard, C., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2169 · Cited by 162
Regulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer
Rennoll, S. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i4.290 · Cited by 162
Adebayo Michael, A. O., Ko, S., Tao, J., Moghe, A., Yang, H., Xu, M., Russell, J. O., Pradhan-Sundd, T., Liu, S., Singh, S., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.002 · Cited by 155 · cited 2×
“Recently, it has been discovered that GS-mediated increased glutamine synthesis leads to mTORC1 activation (90).”
Self-citationWei, W., Chua, M., Grepper, S., & So, S. K. (2009) · International Journal of Cancer · doi:10.1002/ijc.24810 · Cited by 146
Wnt'er in liver: Expression of Wnt and frizzled genes in mouse
Zeng, G., Awan, F. T., Otruba, W., Stock, P., Apte, U. M., Tan, X., Gandhi, C. R., Demetris, A. J., & Monga, S. P. (2006) · Hepatology · doi:10.1002/hep.21473 · Cited by 146
Regulation of c-myc expression by Ras/Raf signalling
Kerkhoff, E., Houben, R., Löffler, S., Troppmair, J., Lee, J., & Rapp, U. R. (1998) · Oncogene · doi:10.1038/sj.onc.1201520 · Cited by 144
Leung, H.-W., Leung, C. O. N., Lau, E. Y.-T., Chung, K. P. S., Mok, E. H. K., Lei, M. M. L., Leung, R. W. H., Tong, M., Keng, V. W., Ma, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0184 · Cited by 140
Austinat, M., Dunsch, R., Wittekind, C., Tannapfel, A., Gebhardt, R., & Gaunitz, F. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-21 · Cited by 139
Tao, J., Xu, E., Zhao, Y., Singh, S., Li, X., Couchy, G., Chen, X., Zucman‐Rossi, J., Chikina, M. D., & Monga, S. P. (2016) · Hepatology · doi:10.1002/hep.28601 · Cited by 139
Self-citationGandhirajan, R. K., Staib, P., Minke, K., Gehrke, I., Plickert, G., Schlösser, A., Schmitt, E. K., Hallek, M. J., & Kreuzer, K. (2010) · Neoplasia · doi:10.1593/neo.91972 · Cited by 134
Liu, R., Li, Y., Tian, L., Shi, H., Wang, J., Liang, Y., Sun, B., Wang, S., Zhou, M., Wu, L., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.030 · Cited by 133
Self-citationShi, W., Dai, M., Zhang, C., Teng, K., Wang, F., Li, H., Sun, W., Feng, Z., Kang, T., Guan, X., et al. (2020) · Protein & Cell · doi:10.1007/s13238-020-00766-y · Cited by 131
Lu, X., Paliogiannis, P., Calvisi, D. F., & Chen, X. (2020) · Hepatology · doi:10.1002/hep.31310 · Cited by 127
Self-citationWnt signaling suppresses MAPK-driven proliferation of intestinal stem cells
Kabiri, Z., Greicius, G., Zaribafzadeh, H., Hemmerich, A. C., Counter, C. M., & Virshup, D. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99325 · Cited by 126
Abitbol, S., Dahmani, R., Coulouarn, C., Ragazzon, B., Mlecnik, B., Senni, N., Savall, M., Bossard, P., Sohier, P., Drouet, V., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.12.018 · Cited by 125
siRNA-Mediated β-Catenin Knockdown in Human Hepatoma Cells Results in Decreased Growth and Survival
Zeng, G., Apte, U. M., Cieply, B. W., Singh, S., & Monga, S. P. (2007) · Neoplasia · doi:10.1593/neo.07469 · Cited by 122
Fan, Z., Duan, J., Wang, L., Xiao, S., Li, L., Yan, X., Yao, W. J., Wu, L., Zhang, S., Zhang, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.040 · Cited by 115
Self-citationThe CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth
Arensman, M. D., Telesca, D., Lay, A. R., Kershaw, K. M., Wu, N., Donahue, T. R., & Dawson, D. W. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1005 · Cited by 114
Shih, Y., Shyu, R., Hsieh, C., Lai, H., Liu, K., Chu, T., & Lin, Y. (2006) · Cancer · doi:10.1002/cncr.22023 · Cited by 113
ICG-001, A Novel Small Molecule Regulator of TCF/β-Catenin Masakatsu Transcription
Eguchi, M., Nguyen, C. K., Lee, S., & Kahn, M. (2005) · Medicinal Chemistry · doi:10.2174/1573406054864098 · Cited by 111
Dihlmann, S., Klein, S., & Mv, M. V. K. D. (2003) · PubMed · Cited by 108
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
Shang, R., Song, X., Wang, P., Zhou, Y., Lu, X., Wang, J., Xu, M. M., Chen, X., Utpatel, K., Che, L., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320716 · Cited by 108
Self-citationMa, L., Wang, X., Jia, T., Wei, W., Chua, M., & So, S. K. (2015) · Oncotarget · doi:10.18632/oncotarget.4455 · Cited by 106
Suzuki, T., Yano, H., Nakashima, Y., Nakashima, O., & Kojiro, M. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02774.x · Cited by 101
Role of Cyclin D1 as a Mediator of c-Met– and β-Catenin–Induced Hepatocarcinogenesis
Patil, M. A., Lee, S. A., Macias, E., Lam, E. T., Xu, C., Jones, K. D., Ho, C., Rodríguez‐Puebla, M. L., & Chen, X. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2514 · Cited by 100
Self-citationHawcroft, G., D'Amico, M., Albanese, C., Markham, A. F., Pestell, R., & Hull, M. A. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.107 · Cited by 100
Tang, B., Tang, F., Wang, Z., Qi, G., Liang, X., Li, B., Yuan, S., Liu, J., Yu, S., & He, S. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0344-9 · Cited by 98
Cheng, H., Sun, G., Chen, H., Yu, L., Han, Z., Li, Y., Zhang, P., Yang, L., & Li, Y. (2019) · PubMed · Cited by 98
QU, B., LIU, B.-R., DU, Y.-J., CHEN, J., CHENG, Y.-Q., XU, W., & WANG, X.-H. (2014) · Oncology Letters · doi:10.3892/ol.2014.1828 · Cited by 96
Liu, Y., Ye, X., Zhang, J.-B., Ouyang, H., Shen, Z., Wu, Y., Wang, W., Wu, J., Tao, S., Yang, X., et al. (2015) · Oncogene · doi:10.1038/onc.2015.7 · Cited by 93
Minke, K., Staib, P., Puetter, A., Gehrke, I., Gandhirajan, R. K., Schlösser, A., Schmitt, E. K., Hallek, M. J., & Kreuzer, K. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01188.x · Cited by 90
Coactivation of AKT and β-Catenin in Mice Rapidly Induces Formation of Lipogenic Liver Tumors
Stauffer, J. K., Scarzello, A. J., Andersen, J. B., Kluyver, R. L. D., Back, T. C., Weiss, J. M., Thorgeirsson, S. S., & Wiltrout, R. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2705 · Cited by 89
Evidence for tankyrases as antineoplastic targets in lung cancer
Busch, A. M., Johnson, K. C., Stan, R. V., Sanglikar, A., Ahmed, Y. F., Dmitrovsky, E., & Freemantle, S. J. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-211 · Cited by 88
Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts
Chiu, M., Tardito, S., Pillozzi, S., Arcangeli, A., Armento, A., Uggeri, J., Missale, G., Bianchi, M. G., Barilli, A., Dall’Asta, V., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.425 · Cited by 87
Tao, J., Zhang, R., Singh, S., Poddar, M., Xu, E., Oertel, M., Chen, X., Ganesh, S., Abrams, M. T., & Monga, S. P. (2016) · Hepatology · doi:10.1002/hep.28975 · Cited by 86
Self-citationBeta-Catenin–NF-κB Interactions in Murine Hepatocytes: A Complex to Die for
Nejak‐Bowen, K. N., Kikuchi, A., & Monga, S. P. (2012) · Hepatology · doi:10.1002/hep.26042 · Cited by 83
Lee, J. M., Yang, J., Newell, P., Singh, S., Parwani, A. V., Friedman, S. L., Nejak‐Bowen, K. N., & Monga, S. P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.020 · Cited by 79
Mizutani, A., Yashiroda, Y., Muramatsu, Y., Yoshida, H., Chikada, T., Tsumura, T., Okue, M., Shirai, F., Fukami, T., Yoshida, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13805 · Cited by 79
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
Pezzuto, F., Izzo, F., Buonaguro, L., Annunziata, C., Tatangelo, F., Botti, G., Buonaguro, F. M., & Tornesello, M. L. (2016) · Oncotarget · doi:10.18632/oncotarget.9801 · Cited by 70
Lo, R. C., Leung, C. O. N., Chan, K. K., Ho, D. W., Wong, C., Lee, T. K., & Ng, I. O. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0059-x · Cited by 70
Stratford, E. W., Daffinrud, J., Munthe, E., Castro, R., Waaler, J., Krauss, S. J. K., & Myklebost, O. (2013) · Cancer Medicine · doi:10.1002/cam4.170 · Cited by 65
Frequent β-catenin aberration in human hepatocellular carcinoma
Fujie, H., Moriya, K., Shintani, Y., Tsutsumi, T., Takayama, T., Makuuchi, M., Kimura, S., & Koike, K. (2001) · Hepatology Research · doi:10.1016/s1386-6346(00)00116-9 · Cited by 63
Lin, H.-H., Feng, W.-C., Lu, L., Shao, Y., Hsu, C., & Cheng, A. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.013 · Cited by 61
Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma
Lee, S. E., Chang, S., Kim, W. Y., Lim, S. D., Kim, W. S., Hwang, T. S., & Han, H. S. (2016) · Oncotarget · doi:10.18632/oncotarget.12121 · Cited by 60
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
Menon, M. R., Elliott, R. J. R., Bowers, L., Balan, N., Rafiq, R., Costa-Cabral, S., Munkonge, F. M., Trinidade, I., Porter, R. A., Campbell, A. D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36447-4 · Cited by 60
Qiao, Y., Wang, J., Karagoz, E., Liang, B.-Y., Song, X., Shang, R., Evert, K., Xu, M. M., Che, L., Evert, M., et al. (2019) · Hepatology · doi:10.1002/hep.30556 · Cited by 60
Self-citationKarabicici, M., Azbazdar, Y., Özhan, G., Şentürk, Ş., Karagonlar, Z. F., & Erdal, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.639779 · Cited by 57
Liang, B., Zhou, Y., Qian, M., Xu, M., Wang, J., Zhang, Y., Song, X., Wang, H., Lin, S., Ren, C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.044 · Cited by 55 · cited 1×
“TBX3 is another liver-specific Wnt/β-catenin target gene that can contribute to specific pathological phenotypes via inhibition of the YAP cascade (94).”
Self-citationβ-Catenin (CTNNB1) Mutations Are Not Associated with Prognosis in Advanced Hepatocellular Carcinoma
Lu, L., Shao, Y., Lee, Y., Hsieh, M., Hsiao, C.-H., Lin, H.-H., Kao, H., Ma, Y.-Y., Yen, F.-C., Cheng, A., et al. (2014) · Oncology · doi:10.1159/000362821 · Cited by 55
Tao, J., Krutsenko, Y., Moghe, A., Singh, S., Poddar, M., Bell, A., Oertel, M., Singhi, A. D., Geller, D., Chen, X., et al. (2021) · Hepatology · doi:10.1002/hep.31730 · Cited by 54
Self-citationDelgado, E. R., Okabe, H., Preziosi, M., Russell, J. O., Alvarado, T. F., Oertel, M., Nejak‐Bowen, K. N., Zhang, Y., & Monga, S. P. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.021 · Cited by 52
Self-citationWang, Z., Sheng, Y., Gao, X., Wang, C., Wang, X., Lu, X., Wei, J., Zhang, K., Dong, Q., & Qin, L. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.569 · Cited by 51
Okada-Iwasaki, R., Takahashi, Y., Watanabe, Y., Ishida, H., Saito, J., Nakai, R., & Asai, A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0938 · Cited by 49
Kaur, P., Mani, S., Cros, M., Scoazec, J., Chemin, I., Hainaut, P. L., & Herceg, Z. (2012) · Tumor Biology · doi:10.1007/s13277-012-0331-5 · Cited by 48
Stabilized β-catenin promotes hepatocyte proliferation and inhibits TNFα-induced apoptosis
Shang, X.-Z., Zhu, H., Lin, K., Tu, Z., Chen, J., Nelson, D. R., & Liu, C. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700043 · Cited by 47
Transcriptomic Characterization of Hepatocellular Carcinoma with CTNNB1 Mutation
Ding, X., Yang, Y., Han, B., Du, C., Xu, N., Huang, H., Cai, T., Zhang, A., Han, Z., Zhou, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095307 · Cited by 47
Chehrazi‐Raffle, A., Dorff, T. B., Pal, S. K., & Lyou, Y. (2021) · Cancers · doi:10.3390/cancers13040889 · Cited by 46
The Wnt inhibitor LGK-974 enhances radiosensitivity of HepG2 cells by modulating Nrf2 signaling
Tian, D., Shi, Y., Chen, D., Liu, Q., & Fan, F. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4042 · Cited by 45
Delgado, E. R., Bahal, R., Yang, J., Lee, S. E., Ly, D. H., & Monga, S. P. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990081 · Cited by 44
Quackenbush, K. S., Bagby, S. M., Tai, W. M. D., Messersmith, W. A., Schreiber, A., Greene, J., Kim, J., Wang, G., Purkey, A., Pitts, T. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8626 · Cited by 43
Liao, X., Song, G., Xu, Z., Bu, Y., Chang, F., Jia, F., Xiao, X., Ren, X., Zhang, M., & Jia, Q. (2020) · BMC Cancer · doi:10.1186/s12885-019-6480-9 · Cited by 40
Self-citationCurrent options and future possibilities for the systemic treatment of hepatocellular carcinoma
Raoul, J., Frenel, J., Raimbourg, J., & Gilabert, M. (2019) · Hepatic Oncology · doi:10.2217/hep-2019-0001 · Cited by 35
Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity
Yang, X., Zhu, L.-C., Wang, Y., Li, Y., & Wang, D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00887 · Cited by 35
Zhang, S., Zhang, J., Evert, K., Li, X., Pin, L., Kiss, A., Schaff, Z., Ament, C. E., Zhang, Y., Serra, M., et al. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.03.011 · Cited by 35
Self-citationLiu, P., Liang, B.-Y., Liu, M., Lebbink, J. H. G., Li, S., Qian, M., Lavrijsen, M., Peppelenbosch, M. P., Chen, X., & Smits, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.11.302 · Cited by 33
Self-citationInterplay of Wnt β-catenin pathway and miRNAs in HBV pathogenesis leading to HCC
Rana, M. A., Ijaz, B., Daud, M., Tariq, S., Nadeem, T., & Husnaın, T. (2018) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2018.09.012 · Cited by 32
Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activation
Ding, Z., Shi, C., Jiang, L., Tolstykh, T., Cao, H., Bangari, D. S., Ryan, S., Levit, M. N., Jin, T. J., Mamaat, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21298 · Cited by 27
Zhan, N., Michael, A. A., Wu, K., Zeng, G., Bell, A. W., Tao, J., & Monga, S. P. (2018) · Gene Expression · doi:10.3727/105221618x15174108894682 · Cited by 27
Qiao, Y., Xu, M. M., Tao, J., Che, L., Cigliano, A., Monga, S. P., Calvisi, D. F., & Chen, X. (2018) · BMC Cancer · doi:10.1186/s12885-018-4870-z · Cited by 26
Self-citationCharawi, S., Just, P., Savall, M., Abitbol, S., Traoré, M., Metzger, N., Ravinger, R., Cavard, C., Terris, B., & Perret, C. (2018) · The Journal of Pathology · doi:10.1002/path.5202 · Cited by 26
Cooperation Between the NRF2 Pathway and Oncogenic β‐catenin During HCC Tumorigenesis
Savall, M., Senni, N., Lagoutte, I., Sohier, P., Dentin, R., Romagnolo, B., Perret, C., & Bossard, P. (2021) · Hepatology Communications · doi:10.1002/hep4.1746 · Cited by 20
Cited by
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
“Although β-catenin has been associated with early-stage HCC, its prognostic significance remains controversial [218].”
BackgroundHepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Borda, M., Sierra, R., Cantero, M. J., Gómez Bustillo, S., Fiore, E. J., Giardelli, G., Martino Garcet, M., Rebottaro, M. L., Bayo Fina, J. M., Schiavone, M., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03896-w · Cited by 3
Metadata
- Authors
- Xu, C., Xu, Z., Zhang, Y., Evert, M., Calvisi, D. F., & Chen, X.
- Venue
- Journal of Clinical Investigation
- Published
- 2022-02-15
- Volume
- 132
- Issue
- 4
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W4212887237
- Cited by
- 305
- References
- 148
- FWCI
- 17.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.